AIM ImmunoTech Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
AIM ImmunoTech engaged Sterling Pharma Solutions for development, analytical validation, and cGMP manufacture of two polynucleotide drug substances—PolyI and Poly C12U—under a proposal dated July 24, 2026, valued at $1,446,200. The work includes process development (12 weeks), non-GMP demonstration batches (3 weeks each), analytical method validation, capital equipment expenditure, and one cGMP batch each of PolyI and Poly C12U solution. Proposal signed by both parties on July 31, 2026; major cost components redacted.
Why this rating
Contract is ~23% of company's $6.4M market value—material commitment. However, filing shows only terms, not receipt of funds or binding commencement. Significance tempered by redacted financials and contingency on AIM's 5-business-day review approvals at multiple gates.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.